Your browser doesn't support javascript.
loading
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Claudiani, Simone; Janssen, Jeroen J W M; Byrne, Jenny; Smith, Graeme; Blijlevens, Nicole; Raghavan, Manoj; Smith, Matthew; Clark, Richard E; Mclain-Smith, Susan; Carter, Angela M; Milojkovic, Dragana; Apperley, Jane F.
Afiliação
  • Claudiani S; Imperial College Healthcare NHS Trust, London, UK.
  • Janssen JJWM; Amsterdam UMC, location VUmc, Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Byrne J; Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Smith G; Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Blijlevens N; Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Raghavan M; Queen Elizabeth Hospital, Birmingham, UK.
  • Smith M; Barts Health NHS Trust, London, UK.
  • Clark RE; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
  • Mclain-Smith S; OPEN Health, Marlow, UK.
  • Carter AM; OPEN Health, Marlow, UK.
  • Milojkovic D; Imperial College Healthcare NHS Trust, London, UK.
  • Apperley JF; Imperial College London, London, UK.
Eur J Haematol ; 109(1): 90-99, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35403752
OBJECTIVES: To describe the real-world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML). METHODS: This was a multi-center, retrospective, non-interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands. RESULTS: Eighty-seven patients were included. Bosutinib was the third-line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth-line in 44 (51%) patients. Median treatment duration was 15.6 months. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due to intolerance to prior TKIs. Cumulative complete cytogenetic and major molecular response rates in CP patients were 67% and 55%, respectively. After a median follow-up of 21.5 months, nine (11%) patients in CP died; estimated overall survival rates at 1 and 2 years postbosutinib initiation were 95% and 91%, respectively. Overall, 33/87 (38%) patients discontinued bosutinib due to either lack of efficacy/disease progression (17%), adverse events (14%), death (2%), or other reasons (5%). Eighty-two (94%) patients experienced ≥1 adverse event possibly related to bosutinib, most commonly diarrhea (52%). CONCLUSIONS: Bosutinib used in routine clinical practice in heavily pretreated patients with CML is an effective treatment for patients in CP and is generally tolerable.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinolinas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Antineoplásicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quinolinas / Leucemia Mielogênica Crônica BCR-ABL Positiva / Antineoplásicos Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans País/Região como assunto: Europa Idioma: En Ano de publicação: 2022 Tipo de documento: Article